No video

Biosimilars: Manufacturing and Inherent Variation

  Рет қаралды 13,021

U.S. Food and Drug Administration

U.S. Food and Drug Administration

2 жыл бұрын

The structure of biological products is typically more complex than small molecule drugs. As a result, biologics are often more complicated to manufacture, process, and purify. They are typically manufactured from living organisms (e.g., microorganisms, animal cells) and therefore, inherently contain many slight variations within lots that are manufactured at different times. This video shows the manufacturing process and how inherent variation occurs naturally in reference products, as well as biosimilar and interchangeable products. For more information, visit www.FDA.gov/biosimilars.

Пікірлер
The Basics of Biosimilars
4:12
U.S. Food and Drug Administration
Рет қаралды 67 М.
Data Requirements for Biosimilars
5:20
U.S. Food and Drug Administration
Рет қаралды 26 М.
👨‍🔧📐
00:43
Kan Andrey
Рет қаралды 10 МЛН
The Joker saves Harley Quinn from drowning!#joker  #shorts
00:34
Untitled Joker
Рет қаралды 58 МЛН
The Biosimilar Development Process
4:20
U.S. Food and Drug Administration
Рет қаралды 36 М.
Biosimilars: Critical Quality Attributes
3:12
U.S. Food and Drug Administration
Рет қаралды 8 М.
The Concept of Interchangeability
4:20
U.S. Food and Drug Administration
Рет қаралды 22 М.
Biomarker Terminology: Speaking the Same Language
5:33
U.S. Food and Drug Administration
Рет қаралды 19 М.
Biosimilars: Approval Process
2:47
U.S. Food and Drug Administration
Рет қаралды 9 М.
Biosimilar Medications - What Patients Need to Know
3:02
U.S. Food and Drug Administration
Рет қаралды 4,9 М.
The Promise of Biosimilars
3:07
U.S. Food and Drug Administration
Рет қаралды 20 М.
What Are Biomarkers And Why Are They Important?
2:05
U.S. Food and Drug Administration
Рет қаралды 73 М.
5 Things You Need to Know About the Drug Approval Process
2:02
U.S. Food and Drug Administration
Рет қаралды 83 М.
4 Tips to Outsmarting Poisonous Plants
2:32
U.S. Food and Drug Administration
Рет қаралды 104 М.